John Reed, MD
Endocrinology, Diabetes & Metabolism · Roswell, GANPI 1194706531
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 36.8% of the total. Reporting peaked in 2021 at $12,416 and has fallen 82.0% since, to $2,240 in 2024. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 946 payments — averaging $28.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$10K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Novo Nordisk AS$1K
- Sanofi-aventis U.S. LLC$1K
- Eli Lilly$1K
- plus $10K from 52 others
Across 3,871 payments — averaging $1476.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2.1M
- Novo Nordisk AS$1.9M
- Eli Lilly$660K
- AbbVie$477K
- Sequel Med Tech, LLC$173K
- Tandem Diabetes Care, Inc.$169K
- plus $273K from 7 others
What the payments were for
- Speaking & faculty fees$9,50035%
- Travel & lodging$1,8387%
- Food & beverage$15,58958%
- Education$1310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$9,500
- iLet Bionic Pancreas$405
- MINIMED 780G$122
How this compares
$27,059 in reported general payments places this provider in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 251 | $301,026 |
| OzempicSemaglutide | 200 | $286,798 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 92 | $112,379 |
| JardianceEmpagliflozin | 73 | $101,883 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 73 | $79,139 |
| FarxigaDapagliflozin Propanediol | 56 | $73,902 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $54,967 |
| SynthroidLevothyroxine Sodium | 464 | $51,187 |
| TrulicityDulaglutide | 35 | $47,649 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $42,069 |
| NovologInsulin Aspart | 95 | $36,684 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $35,198 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $27,466 |
| Novolog FlexpenInsulin Aspart | 95 | $24,282 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $18,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $1,571 | $386,830388 claims |
| Novo NordiskOzempic, Novolog, Levemir | $2,058 | $328,510311 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,263 | $115,331121 claims |
| Boehringer IngelheimJardiance | $439 | $101,88373 claims |
| AstraZenecaFarxiga | $286 | $73,90256 claims |
| AbbVieSynthroid | $390 | $51,187464 claims |
| Esperion Therapeutics, Inc.Nexlizet | $235 | $18,34025 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $163 | $8,411790 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Roswell
- Arjun HaridasRoswell$13K
- Muhammad SiddiquiRoswell$11K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.